12:00 AM
 | 
Dec 07, 2015
 |  BioCentury  |  Finance

Hard to resist

Why investors in Aragon, Seragon are coming back for thirds with Oric

The team and investors behind drug-resistant cancer companies Aragon Pharmaceuticals Inc. and Seragon Pharmaceuticals Inc. are back for thirds with Oric Pharmaceuticals Inc., which hopes to take a broader approach than its predecessors by focusing on resistance mechanisms in multiple oncology indications rather than in a single tumor type.

Last week, Oric raised $53 million in a series B round with The Column Group, Topspin Partners, OrbiMed, EcoR1, Foresite and Kravis Investment.

The first three investors have been...

Read the full 396 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >